Inventor · disambiguated record
Yosef Yarden
Also filed as: YARDEN YOSEF
14 granted patents·14 pending applications·115 citations·filing 2000–2023
90Inventor score
Top patents by PatentIndex Score
28 records- 0197US7939072B2Anti-EGFR antibodies with an improved anti-tumor activity and compositions and articles of manufacture comprising sameYEDA RES & DEV·Filed 2009·Granted May 10, 2011·46 cites·2 claims
- 0296US7498142B2Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodiesYEDA RES & DEV·Filed 2006·Granted Mar 3, 2009·31 cites·11 claims
- 0386US7094882B2Growth factor which acts through erb b-4 rtkYEDA RES & DEV·Filed 2001·Granted Aug 22, 2006·13 cites·3 claims
- 0482US6544759B1Polynucleotides encoding a novel growth factor which acts through ErbB-4 kinase receptor tyrosineYEDA RES & DEV·Filed 2000·Granted Apr 8, 2003·21 cites·8 claims
- 0579US7981997B2Growth factor which acts through ErbB-4 RTKYEDA RES & DEV·Filed 2009·Granted Jul 19, 2011·2 cites·4 claims
- 0671US8883149B2Antibody combinations and use of same for treating cancerSELA MICHAEL·Filed 2009·Granted Nov 11, 2014·2 cites·3 claims
- 0766US9358288B2Antibody combinations and use of same for treating cancerYEDA RES & DEV·Filed 2014·Granted Jun 7, 2016·0 cites·5 claims
- 0866US2024156959A1COMBINATION THERAPY FOR THE TREATMENT OF CANCER COMPRISING AN ANTl-EGFR ANTIBODY AND AN AXL-INHIBITORYEDA RES & DEV·Filed 2023·Application pending·0 cites
- 0963US2007015196A1Growth factor with acts through Erb B-4 RTKYEDA RES & DEV·Filed 2006·Application pending·0 cites
- 1061US2011236975A1Growth factor which acts through erb b-4 rtkYEDA RES & DEV·Filed 2011·Application pending·0 cites
- 1158US9926564B2Aptamers, multimeric aptamers and uses thereofYEDA RES & DEV·Filed 2013·Granted Mar 27, 2018·0 cites·11 claims
- 1255US10640556B2Anti amphiregulin antibodies, compositions comprising same and uses thereofYEDA RES & DEV·Filed 2018·Granted May 5, 2020·0 cites·9 claims
- 1355US2021275545A1Method of treating cancer preferably characterized by expression of a fusion protein comprising a member of the e-twenty-six family by administering an agent that inhibits the synthesis and/or activity of cortisolYEDA RES & DEV·Filed 2021·Application pending·0 cites
- 1454US2011183437A1Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodiesYEDA RES & DEV·Filed 2011·Application pending·0 cites
- 1551US2017042857A1Synaptojanin-2 inhibitors for use in the treatment of cancerYEDA RES & DEV·Filed 2014·Application pending·0 cites
- 1651US2017165285A1Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitorsYEDA RES & DEV·Filed 2017·Application pending·0 cites
- 1750US2015266970A1Combinations of epidermal growth factor receptor targeting antibodies for treating cancerYEDA RES & DEV·Filed 2013·Application pending·0 cites
- 1849US2018208674A1Combinations of epidermal growth factor receptor targeting antibodies for treating cancerYEDA RES & DEV·Filed 2018·Application pending·0 cites
- 1947US2015290233A1Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitorsYEDA RES & DEV·Filed 2013·Application pending·0 cites
- 2044US2017122950A1ANTIBODIES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASESYEDA RES & DEV·Filed 2016·Application pending·0 cites
- 2140US9415103B2Combination therapy to prevent DCIS formation and progression to breast cancerYARDEN YOSEF·Filed 2012·Granted Aug 16, 2016·0 cites·23 claims
- 2238US9518988B2Antibodies and methods of using same for treating ErbB/ErbB ligands associated diseasesLINDZEN MOSHIT·Filed 2011·Granted Dec 13, 2016·0 cites·6 claims
- 2337US9040047B2Combinations of anti ErbB antibodies for the treatment of cancerSELA MICHAEL·Filed 2012·Granted May 26, 2015·0 cites·19 claims
- 2436US10526416B2Anti-HER3 antibodies and uses of sameYEDA RES & DEV·Filed 2015·Granted Jan 7, 2020·0 cites·11 claims
- 2536US2007077628A1Polynucleotides, polypeptides and antibodies and use thereof in treating tsg101-associated diseasesYARDEN YOSEF·Filed 2006·Application pending·0 cites
- 2636US2017002068A1Anti amphiregulin antibodies, compositions comprising same and uses thereofYEDA RES & DEV·Filed 2016·Application pending·0 cites
- 2732US2017196888A1Compositions and methods for treating cancerYEDA RES & DEV·Filed 2015·Application pending·0 cites
- 2827US10011659B2Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI)YEDA RES & DEV·Filed 2015·Granted Jul 3, 2018·0 cites·15 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →